Osman Khan, MD
Pediatric Hematology-Oncology · Oklahoma City, OKNPI 1942412150
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $97,927 of the $140,019 with a category attached, or 69.9%. 14 manufacturers reported payments, led by Sanofi at 25.6% of the total. Among pediatric hematology-oncology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 147 payments — averaging $952.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$36K
- Genentech USA, Inc.$30K
- Biomarin Pharmaceutical Inc.$14K
- Shire North American Group Inc$13K
- CSL Behring$12K
- Bayer$11K
- plus $25K from 8 others
Across 66 payments — averaging $2067.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$64K
- Novo Nordisk AS$45K
- Pfizer$13K
- Bayer$13K
- HEMA Biologics, LLC$2K
- Daiichi Sankyo Inc.$41
What the payments were for
- Consulting fees$97,92770%
- Speaking & faculty fees$19,46614%
- Travel & lodging$17,04412%
- Food & beverage$5,5824%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 22 | $35,831 |
| Genentech USA, Inc. | 30 | $29,875 |
| Biomarin Pharmaceutical Inc. | 17 | $13,712 |
| Shire North American Group Inc | 14 | $13,191 |
| CSL Behring | 18 | $11,609 |
| Bayer | 14 | $10,749 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $9,037 |
| Pfizer | 6 | $6,368 |
| Novo Nordisk | 8 | $5,831 |
| Kedrion Biopharma Inc. | 1 | $2,662 |
| Octapharma USA, Inc. | 1 | $1,000 |
| Sobi, Inc | 1 | $116 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Incyte Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$140,019 in reported general payments places this provider in the 95th percentile of 25 pediatric hematology-oncology providers in Oklahoma.
See all pediatric hematology-oncology providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pediatric hematology-oncology in Oklahoma City
- Rikin ShahOklahoma City$86K
- William MeyerOklahoma City$6K
- Rene McNall-KnappOklahoma City$4K
- Ashley BakerOklahoma City$1K
- Suraj PratapOklahoma City$1K
- Rachel PoseyOklahoma City$774
- Sayani TewariOklahoma City$420
- Hanumantha PokalaOklahoma City$326
- Rachel GallantOklahoma City$324
- Jessica KurianOklahoma City$300
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.